ERBB2 and breast carcinoma: In a study of 21 patients with stage IV HER2-positive breast cancer being treated with trastuzumab, Disis et al. showed that concurrent vaccination with a vaccine designed to elicit HER2-specific T-helper immunity was safe [17].